{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:13:13Z","timestamp":1771992793730,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jfma.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T23:45:58Z","timestamp":1737416758000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes of chronic myeloid leukemia in children and adolescents \u2013 Real world data from a single-institute in Taiwan"],"prefix":"10.1016","volume":"125","author":[{"given":"Yuan-Ning","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ying","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiann-Shiuh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Hsuan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-9511","authenticated-orcid":false,"given":"Chao-Neng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.01.014_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41416-023-02162-9","article-title":"Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan","volume":"128","author":"Liu","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jfma.2025.01.014_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2025.01.014_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/blood.V72.1.294.294","article-title":"Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia","volume":"72","author":"Sokal","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2025.01.014_bib6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jfma.2025.01.014_bib8","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","article-title":"Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I","volume":"221","author":"Suttorp","year":"2009","journal-title":"Klin P\u00e4diatr"},{"key":"10.1016\/j.jfma.2025.01.014_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","article-title":"Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years","volume":"167","author":"de la Fuente","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jfma.2025.01.014_bib11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2025.01.014_bib12","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.2019000069","article-title":"Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2025.01.014_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2025.01.014_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26959","article-title":"Allogeneic stem cell transplantation for children and adolescents\/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era","volume":"98","author":"Ishida","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2025.01.014_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.jfma.2025.01.014_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jfma.2025.01.014_bib18","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2025.01.014_bib19","first-page":"2555","article-title":"Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort","volume":"109","author":"Stiehler","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jfma.2025.01.014_bib20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","article-title":"A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety","volume":"5","author":"Hijiya","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jfma.2025.01.014_bib21","doi-asserted-by":"crossref","first-page":"7279","DOI":"10.1182\/bloodadvances.2023010122","article-title":"The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study","volume":"7","author":"Hijiya","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jfma.2025.01.014_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2025.01.014_bib25","unstructured":"Hijiya N, Zwaan CM, Rizzari C, Foa R, Abbink F, Lancaster D, et al. Nilotinib in pediatric patients with Philadelphia chromosome-positive (PH plus) chronic myeloid leukemia (CML) or PH plus acute lymphoblastic leukemia (ALL): a pharmacokinetic study. In: Pediatric blood & CANCER2017. S34-S."},{"key":"10.1016\/j.jfma.2025.01.014_bib26","unstructured":"SPRYCEL (dasatinib) U.S. Prescribing Information. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf [Accessed December 19, 2024]."},{"key":"10.1016\/j.jfma.2025.01.014_bib27","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2025.01.014_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1875-9572(10)60014-9","article-title":"New growth charts for Taiwanese children and adolescents based on World Health Organization standards and health-related physical fitness","volume":"51","author":"Chen","year":"2010","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.jfma.2025.01.014_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/adc.41.220.613","article-title":"Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II","volume":"41","author":"Tanner","year":"1966","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jfma.2025.01.014_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.HS9.0000559876.36369.09","article-title":"PF416 growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"3","author":"Patterson","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.jfma.2025.01.014_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153862","article-title":"Front-line tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: a study on efficacy and safety","volume":"15","author":"Yoo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jfma.2025.01.014_bib32","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2025.01.014_bib33","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jfma.2025.01.014_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2025.01.014_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164102","article-title":"Discontinuation of imatinib in children with chronic myeloid leukemia: a study from the international registry of childhood CML","volume":"13","author":"Millot","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jfma.2025.01.014_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29699","article-title":"Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia","volume":"69","author":"Shima","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jfma.2025.01.014_bib37","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2024-198938","article-title":"Growth retardation and adult height in children with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"144","author":"Shima","year":"2024","journal-title":"Blood"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:22:58Z","timestamp":1771989778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0929664625000142"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of chronic myeloid leukemia in children and adolescents \u2013 Real world data from a single-institute in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}